A phase II study of sorafenib in malignant mesothelioma: Results of Cancer and Leukemia Group B 30307

Journal of Thoracic Oncology

Volumn 5, Issue 10, 2010, Pages 1655-1661

  Dubey, Sarita ^a   Jänne, Pasi A ^b   Krug, Lee ^c   Pang, Herbert ^d   Wang, Xiaofei ^d   Heinze, Robin ^d   Watt, Colleen ^e   Crawford, Jeff ^d   Kratzke, Robert ^f   Vokes, Everett ^g   Kindler, Hedy Lee ^g  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^d DUKE UNIVERSITY MEDICAL CENTER   (United States)

^e Cancer and Leukemia Group B Central Office   (United States)

^f UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^g UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

Author keywords

Clinical trial; Mesothelioma; Sorafenib; Tyrosine kinase inhibitor; Vascular endothelial growth factor

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; SORAFENIB;

ADULT; AGED; ANOREXIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CANCER SURVIVAL; CLINICAL TRIAL; CONTINUOUS INFUSION; DRUG ACTIVITY; DRUG INHIBITION; DYSPNEA; ENZYME PHOSPHORYLATION; FATIGUE; FEMALE; HEMOGLOBINOPATHY; HEMOLYSIS; HISTOLOGY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPERTENSION; HYPOTENSION; IMMUNOHISTOCHEMISTRY; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PAIN; PHASE 2 CLINICAL TRIAL; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RASH; SENSORY NEUROPATHY; TREATMENT RESPONSE;

EID: 77958167230     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e3181ec18db     Document Type: Article

References (29)

1. Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003;21: 2636-2644. (Pubitemid 46606305)
2. Dvorak HF. Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol 2002;20:4368-4380.
3. Strizzi L, Catalano A, Vianale G, et al. Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma. J Pathol 2001;193:468-475. (Pubitemid 32266815)
4. Ohta Y, Shridhar V, Bright RK, et al. VEGF and VEGF type C play an important role in angiogenesis and lymphangiogenesis in human malignant mesothelioma tumours. Br J Cancer 1999;81:54-61. (Pubitemid 29415491)
5. Takahashi T, Ueno H, Shibuya M. VEGF activates protein kinase C-dependent, but ras-independent Raf-MEK-MAP kinase pathway for DNA synthesis in primary endothelial cells. Oncogene 1999;18:2221-2230. (Pubitemid 29186923)
6. Versnel MA, Claesson-Welsh L, Hammacher A, et al. Human malignant mesothelioma cell lines express PDGF beta-receptors whereas cultured normal mesothelial cells express predominantly PDGF alpha-receptors. Oncogene 1991;6:2005-2011. (Pubitemid 21924040)
7. Whitson BA, Kratzke RA. Molecular pathways in malignant pleural mesothelioma. Cancer Lett 2006;239:183-189. (Pubitemid 43996826)
8. Klominek J, Baskin B, Hauzenberger D. Platelet-derived growth factor (PDGF) BB acts as a chemoattractant for human malignant mesothelioma cells via PDGF receptor beta-integrin alpha3beta1 interaction. Clin Exp Metastasis 1998;16:529-539. (Pubitemid 29009588)
9. Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004;64:7099-7109. (Pubitemid 39331023)
10. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007;356:125-134. (Pubitemid 46089673)
11. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378-390.
12. Byrne MJ, Nowak AK. Modified RECIST criteria for assessment of response in malignant pleural mesothelioma. Ann Oncol 2004;15:257-260. (Pubitemid 38262625)
13. Steele JP, Shamash J, Evans MT, et al. Phase II study of vinorelbine in patients with malignant pleural mesothelioma. J Clin Oncol 2000;18: 3912-3917.
14. Kindler HL, Millard F, Herndon JE II, et al. Gemcitabine for malignant mesothelioma: a phase II trial by the Cancer and Leukemia Group B. Lung Cancer 2001;31:311-317. (Pubitemid 32107026)
15. Stebbing J, Powles T, McPherson K, et al. The efficacy and safety of weekly vinorelbine in relapsed malignant pleural mesothelioma. Lung Cancer 2009;63:94-97.
16. van Meerbeeck JP, Gaafar R, Manegold C, et al. Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. J Clin Oncol 2005;23:6881-6889. (Pubitemid 46260274)
17. Abou-Alfa GK, Schwartz L, Ricci S, et al. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 2006;24: 4293-4300. (Pubitemid 46630787)
18. Hayat MJ, Howlader N, Reichman ME, et al. Cancer statistics, trends, and multiple primary cancer analyses from the Surveillance, Epidemiology, and End Results (SEER) Program. Oncologist 2007;12:20-37. (Pubitemid 46143500)
19. Karrison T, Kindler HL, Gandara DR, et al. Final analysis of a multicenter, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin (GC) plus bevacizumab (B) or placebo (P) in patients (pts) with malignant mesothelioma (MM). J Clin Oncol 2007; 18s:Abstract 7526.
20. Francart J, Vaes E, Henrard S, et al. A prognostic index for progressionfree survival in malignant mesothelioma with application to the design of phase II trials: a combined analysis of 10 EORTC trials. Eur J Cancer 2009;45:2304-2311.
21. Krug LM, Curley T, Schwartz L, et al. Potential role of histone deacetylase inhibitors in mesothelioma: clinical experience with suberoylanilide hydroxamic acid. Clin Lung Cancer 2006;7:257-261. (Pubitemid 43280028)
22. Tsao AS, Wistuba I, Roth JA, et al. Malignant pleural mesothelioma. J Clin Oncol 2009;27:2081-2090.
23. Tsao AS, He D, Saigal B, et al. Inhibition of c-Src expression and activation in malignant pleural mesothelioma tissues leads to apoptosis, cell cycle arrest, and decreased migration and invasion. Mol Cancer Ther 2007;6:1962-1972. (Pubitemid 47052486)
24. Jahan T, Gu L, Wang X, et al. Vatalanib in patients with previously untreated advanced malignant mesothelioma: preliminary analysis of a phase II study by the Cancer and Leukemia Group B (CALGB 30107). Lung Cancer 2005;49(S2):Abstract P403.
25. Baas P, Boogerd W, Dalesio O, et al. Thalidomide in patients with malignant pleural mesothelioma. Lung Cancer 2005;48:291-296. (Pubitemid 40501820)
26. Kindler HL, Vogelzang NJ, Chien K, et al. SU5416 in malignant mesothelioma: a University of Chicago phase II consortium study. Proc Am Soc Clin Oncol 2001;20:Abstract 1359.
27. Pavlakis N, Abraham R, Harvie R, et al. Thalidomide alone or in combination with cisplatin/gemcitabine in malignant pleural mesothelioma: interim results from two parallel non randomized phase II studies. Lung cancer 2003;41(S2):S11.
28. Nowak AK, Milward MJ, Francis R, et al. Phase II study of sunitinib as second-line therapy in malignant pleural mesothelioma (MM). J Clin Oncol 2008;26:Abstract 2063.
29. Garland LL, Redman M, Wozniak A, et al. A phase II study of novel oral antiangiogenic agent AZD2171 (NSC-732208) in malignant pleural mesothelioma. J Clin Oncol 2009;27(15s):Abstract 7511.